2019 CYIR Finalized
51 LUNG CANCER Sam Janes, PhD University College London London, United Kingdom NIVOLUMAB PLUS IPILIMUMAB IN LUNG CANCER WITH A HIGH TUMOR MUTATIONAL BURDEN: CHECKMATE 227 Hellmann MD, Ciuleanu TE, Pluzanski A et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018; 378(22):2093- 2104 Summary Through immune checkpoint blockade, several studies have demonstrated striking anti-tumour responses when monoclonal antibodies against co-inhibitory domains on immune cells are disengaged. Hellmann et al report their findings following completion of a phase III clinical trial where 550 patients with treatment naïve advanced NSCLC were randomized (1:1:1) to either a) nivolumab + ipilim- umab b) nivolumab (240mg if PD-L1 greater/equal to 1% or 360mg + chemotherapy (CT) if less than 1% or c) CT. As per standard of care, maintenance pemetrexed was given to those following chemotherapy with non-squa- mous pathology. Crossover was not permitted. Using the Foundation Medicine 1 assay, tumour mutational burden (TMB) was calculated. In those with high TMB (identified as 10 or more mutations per megabase) combination immu- notherapy demonstrated a longer 1-year progression free survival (PFS) compared with CT alone (42.6% vs. 13.2%, HR=0.58, p<0.001) and median PFS was longer (7.2m vs. 5.5m, HR=0.58, p<0.001). In addition, overall response rate (ORR - 45.3% vs. 26.9%) and duration of response [DoR Not reached NR (95% CI=12.8 to NR) vs. 5.4m (4.2-6.9)] were also higher in this group. Comments 1. TMB is a useful predictive biomarker of response, although there was no correlation with PD-L1 expression. 2. The success rate of obtaining TMB was only 58%, although the authors believe this can be improved in clinical practice if test- ing is performed earlier in the treatment pathway. 3. The PFS KM curves begin to plateau at time of analysis, sug- gesting a longer duration of response in subsequent analyses. 4. Immunotherapy given up to 2 years; is this enough? 5. Toxicity of doublet immunotherapy is less than CT but more than anti-PD1 monotherapy. NEOADJUVANT PD-1 BLOCKADE IN RESECTABLE LUNG CANCER Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 2018; 378(21):1976-1986 Summary Surgical management of NSCLC is infrequently coupled with systemic treatment. Adjuvant chemotherapy provides modest outcomes in a select few. In a pilot study, patients with stage I-IIIA NSCLC were recruited to receive two pre- operative doses of nivolumab (3mg/kg) prior to resection of their tumour. Following the removal of 21 tumours, 20 of which were completely removed, 9 out of 20 underwent a major pathological response (45%) meaning 10% or less of the tumour at pathological review was viable. Response could be predicted based on tumour mutational burden. Those with the highest (TMB) correlated with a major pathological response compared to those with lower levels. Evidence of T cell priming was also shown in an individual case where specific T cell clones against anti-tumour neo- antigens expanded in the circulation following anti-PD1 therapy. Also see the NADIM study (recommended text), an unrelated phase II single arm study utilizing nivolumab with CT both pre- and post surgery up to 1 year. Early data has suggested a complete response rate of 62% in 13 cases, although this requires further maturation. Comments 1. Pathological responses have been seen in less cases (approxi- mately 20%) who received neoadjuvant CT, which correlated with survival. 2. Maturation of this study is necessary in order to observe a sur- vival benefit, but results are encouraging. 3. Pathological response did not correlate with radiological response but it did with TMB. 4. Priming of anti-tumour T cells could help target cancer cells elsewhere (micrometastases). 5. No delays to surgery occurred. OVERALL SURVIVAL WITH DURVALUMAB AFTER CHEMORADIOTHERAPY IN STAGE III NSCLC (PACIFIC) Antonia SJ, Villegas A, Daniel D et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379(24):2342-2350 Summary The rationale of combining radiation therapy with immune checkpoint inhibition is best exemplified by the multina- tional phase III PACIFIC clinical trial. 713 patients were recruited with unresectable stage III NSCLC, to receive 2 cycles of platinum based chemotherapy concurrently with definitive doses of radiation therapy followed by either the anti-PD-L1 monoclonal antibody durvalumab (10mg/kg) (n=473) or placebo (n=236) up to 12 months. At 24 months WEDNESDAY, MAY 22 LUNG CANCER
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw